Preliminary Programme

**Monday, 15 November 2021 – 1599 at the Royal College Glasgow**

10.00 – 17.00  LES100 Training Course

18.45 – 19.30  Civic Reception hosted by Glasgow City Council

19.30  Gala Dinner with Guest Speaker (Lindesay Low, Scotch Whisky Association)

**Tuesday, 16 November 2021 – Radisson Blu Hotel**

09.00 – 09.25  Registration with Tea/Coffee

09.25 – 09.30  LES Britain & Ireland President’s Welcome

*Patrick Cantrill, Senior Counsel, Womble Bond Dickinson (UK) LLP*

09.30 – 10.45  Panel: Deal making trends and outlook for the Life sciences industry – The industry has faced a very challenging but interesting time over the last couple of years – how has the industry reacted as a whole and what next for our deal making?

*Moderator: Hayley French, Chief Executive Officer, Apitope*

*Panellists: Michael Murray, Head of Business Development, Enterobiotex*

*Craig Johnston, Chief Technology Officer, ENOUGH*

10.45 – 11.30  Public Support for Start-up Ventures

*Speaker: Nicola McMillan, Team Leader - High Growth Spin Out Programme, Scottish Enterprise*

- What public support and grant / equity funding is available to start-up and spin-out early-stage enterprises?
- How has COVID affected the situation over the past few months?
- From the perspective of a start-up CEO or a university technology transfer office, how can these schemes best be used and what are the key constraints?

11.30 – 11.45  Tea/Coffee Break

11.45 – 13:00  Panel: Commercialisation of the Academic Research Base

*Moderator: Samantha Williams, Licensing Manager, Trinity College Dublin*

*Panellists: David Pritchard, Technology Transfer Manager, Edinburgh Innovations*

*Neil Gordon, Start-up Development Manager, Trinity College Dublin*

*Catherine Breslin, Head of IP & Commercialisation, University of Strathclyde*

Panel members will represent different perspectives and institutions across Britain and Ireland and will cover topical areas in licensing from the academic research base. Topics covered will include challenges, learnings, and initiatives in academic research IP licensing through the pandemic and the potential future impacts, as well as general trends in IP licensing and policy from the academic sector based on the experience of the Panel.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00 – 14.00</td>
<td>Lunch</td>
</tr>
</tbody>
</table>
| 14.00 – 14.45 | **Keynote: Irn-Bru: Protecting a Heritage Brand**  
*Speaker: Stephen Taylor, Legal Counsel, AG Barr*  
Stephen Taylor will review the interesting history of the iconic Scottish brand, Irn-Bru, and give some insights on their approach to brand protection and licensing. Stephen will also discuss how they have adapted their strategy over the years, particularly in recent times, to deal with modern challenges. |
| 14.45 – 15.30 | **Keynote: No one is safe until everyone is safe - the story behind CEPI’s R&D partnerships and supporting the COVAX Mission**  
*Speaker: Emma Wheatley, Deputy General Counsel & Head of Business Development, Coalition for Epidemic Preparedness Innovations (CEPI)*  
This session will discuss how CEPI funded academia and industry work from the creation of constructs to the approval of vaccines for emergency use within a year. The opportunities and challenges of the work taken on in partnership by CEPI, Gavi, WHO and UNICEF for the development, procurement, allocation and deployment of vaccines to the World through COVAX against a background of increasing national concerns, the validation of new technologies and supply shortages. |
| 15.30 – 15:45 | Tea/Coffee Break                                                     |
| 15.45 – 16.30 | **Agreements to Supply Products in a Time of Shortage**  
*Speaker: Dai Davis, Solicitor, Percy Crow Davis & Co*  
You can’t make something out of nothing. If you are a supplier of a product and you can’t make enough of that product, keeping all your customers happy is always going to be an issue. But compounding the problem by not dealing with that potential situation in a contract, especially when a shortage can easily be envisaged, is certainly going to be unhelpful. As we have recently seen in the topical Belgian case of European Commission -v- AstraZeneca. Dai’s talk is not however an analysis of that case nor is the talk focused on vaccines. Rather, Dai will discuss what you should generally do to avoid litigation. |
| 16.30 – 16.45 | Closing Address                                                      |

Kindly sponsored by

![Womble Bond Dickinson](image)